|
Mar 28
|
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
|
|
Mar 13
|
Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares
|
|
Mar 6
|
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
|
|
Mar 4
|
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
|
|
Jan 4
|
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
|
|
Dec 19
|
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
|
|
Dec 18
|
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
|
|
Dec 6
|
13 Hot Penny Stocks To Buy According to Hedge Funds
|
|
Dec 5
|
Semtech (SMTC) to Release Q3 Earnings: What's in the Cards?
|
|
Dec 5
|
Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?
|
|
Nov 27
|
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
|
|
Sep 15
|
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has caught the attention of institutional investors who hold a sizeable 43% stake
|
|
Jul 6
|
Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum
|
|
Jun 23
|
Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
|
|
Jun 21
|
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191
|
|
Jun 16
|
Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study
|
|
Jun 15
|
Why Aldeyra Therapeutics Stock Is Trading Higher Today
|
|
Jun 15
|
Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis
|
|
Jun 14
|
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
|
|
Feb 7
|
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
|